Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows

Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows
Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those subsequent therapies, a Phase 3 trial found. The exploratory analysis from the ARIEL3 Phase 3 trial (NCT01968213) was discussed during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held recently in Chicago. The findings were presented in the poster, “Exploratory analysis of the effect of maintenance rucaparib on post-progression outcomes in patients with platinum-sensitive recurrent ovarian carcinoma and updated safety data from the phase 3 study ARIEL3.” ARIEL3 included 564 women with recurrent ovarian cancer who were responding to platinum-based chemotherapy. The trial sought to determine if Clovis Oncology's Rubraca maintenance kept patients without disease progression for longer periods, regardless of their BRCA status. The results showed that maintenance with Rubraca extended the time women lived without disease worsening from 5.4 months to 10.8 months. That 64% reduction in the risk of disease progression or death convinced both the
Subscribe or to access all post and page content.